Roger B. Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Roger B. Cohen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Charu Aggarwal
University of Pennsylvania, Philadelphia, PA
3 shared publications - Joshua Bauml
University of Pennsylvania, Philadelphia, PA
2 shared publications A P Mazar
Attenuon, LLC San Diego, CA, USA
1 shared publicationAfshin Dowlati
Case Western Reserve University, Cleveland, OH
1 shared publicationAjeeta Dash
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
1 shared publicationAlbert C. Lockhart
Division of Oncology, Washington University School of Medicine, Saint Louis, MO
1 shared publication
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 6073
Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).
6073 Background: Oropharyngeal HNSCCa is frequently associated with HPV. We hypothesize that immunotherapy with INO-3112 will generate immune responses in patients (pts) with HPV+ HNSCCa. Methods: This Phase I/IIa trial included pts with p16+ locally advanced HNSCCa, ECOG PS 0-1. INO-3112 was delivered IM along with electroporation with the CELLECTRA device, Q3 weeks x 4 doses. Cohort 1 (C1) pts received INO-3112 pre and post-surgery; Cohort 2 (C2) pts received INO-3112 post cisplatin-based definitive chemoradiation. 1° and 2° endpoints were safety and immune responses. Pre- and post INO-3112 tissue samples (C1) were assessed for tumor infiltrating lymphocytes (TILs). Peripheral immune responses were assessed by ELISA for HPV16/18 specific antibody levels, and by IFNɤ ELISpot for antigen specific response, at each dose visit and q3 months (mos). Results: As of 08/2016, 22 pts were treated, completing accrual. C1: n = 6, C2: n = 16; 20 male, median age 57.5 years (32-76); base of tongue = 10, tonsil = 12; never smoker = 10. All pts are alive, median follow up is 15.9 mos (1-26). INO-3112 was well-tolerated with no related Grade 3-5 AEs. In 5 C1 pts post immunotherapy, increase in CD8+ infiltration into tumor was noted in 2 pts (1.6-3.6 fold) and decrease in FoxP3+ was noted in the other 3 (1.8-2.1 fold). This resulted in positive shift in CD8+/FoxP3+ ratio in neoplastic tissue in 4/5 pts. Peak mean/median antibody responses to HPV16 E7 and HPV18 E7 antigens for 19 evaluable pts were 1:1235/1:150 and 1:2853/1:450, respectively. As compared to baseline, 18 evaluable pts showed elevated HPV16/HPV18 specific T cell activity (by IFNɤ ELISpot), with peak mean/median responses of 179.99/68.33 SFU per 106 PBMC (HPV16) and 107.18/53.3 SFU per 106 PBMC (HPV18). Persistent cellular responses > 100 SFU/106PBMC were noted out to 12 mos. 3 pts have progressed; 1 pt received Nivolumab for progressive disease, and remains in CR. Conclusions: These data show that INO-3112 generates HPV-specific peripheral humoral and cellular immune responses that may persist out to 12 months and influences the composition of CD8+ and FoxP3+ immune infiltration into tumor tissue in HPV+ HNSCCa. Clinical trial information: NCT02163057.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 6073
Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).
6073 Background: Oropharyngeal HNSCCa is frequently associated with HPV. We hypothesize that immunotherapy with INO-3112 will generate immune responses in patients (pts) with HPV+ HNSCCa. Methods: This Phase I/IIa trial included pts with p16+ locally advanced HNSCCa, ECOG PS 0-1. INO-3112 was delivered IM along with electroporation with the CELLECTRA device, Q3 weeks x 4 doses. Cohort 1 (C1) pts received INO-3112 pre and post-surgery; Cohort 2 (C2) pts received INO-3112 post cisplatin-based definitive chemoradiation. 1° and 2° endpoints were safety and immune responses. Pre- and post INO-3112 tissue samples (C1) were assessed for tumor infiltrating lymphocytes (TILs). Peripheral immune responses were assessed by ELISA for HPV16/18 specific antibody levels, and by IFNɤ ELISpot for antigen specific response, at each dose visit and q3 months (mos). Results: As of 08/2016, 22 pts were treated, completing accrual. C1: n = 6, C2: n = 16; 20 male, median age 57.5 years (32-76); base of tongue = 10, tonsil = 12; never smoker = 10. All pts are alive, median follow up is 15.9 mos (1-26). INO-3112 was well-tolerated with no related Grade 3-5 AEs. In 5 C1 pts post immunotherapy, increase in CD8+ infiltration into tumor was noted in 2 pts (1.6-3.6 fold) and decrease in FoxP3+ was noted in the other 3 (1.8-2.1 fold). This resulted in positive shift in CD8+/FoxP3+ ratio in neoplastic tissue in 4/5 pts. Peak mean/median antibody responses to HPV16 E7 and HPV18 E7 antigens for 19 evaluable pts were 1:1235/1:150 and 1:2853/1:450, respectively. As compared to baseline, 18 evaluable pts showed elevated HPV16/HPV18 specific T cell activity (by IFNɤ ELISpot), with peak mean/median responses of 179.99/68.33 SFU per 106 PBMC (HPV16) and 107.18/53.3 SFU per 106 PBMC (HPV18). Persistent cellular responses > 100 SFU/106PBMC were noted out to 12 mos. 3 pts have progressed; 1 pt received Nivolumab for progressive disease, and remains in CR. Conclusions: These data show that INO-3112 generates HPV-specific peripheral humoral and cellular immune responses that may persist out to 12 months and influences the composition of CD8+ and FoxP3+ immune infiltration into tumor tissue in HPV+ HNSCCa. Clinical trial information: NCT02163057.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3081
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
3081 Background: GMCI is a tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followed by administration of an anti-herpetic prodrug. Immunogenic tumor cell death and superantigen-mediated T cell stimulation leads to CD8 T cell dependent protection against tumor challenge in preclinical models. Methods: The primary end-point of this dose escalation trialwas safety of GMCI followed by standard chemotherapy. Eligibility included patients (pts) with MPE with a clinical indication for placement of pleural catheter, age > 18 yrs, ECOG PS 0-1, FEV1 > 40% predicted and adequate end organ function. Intra-pleural (IP) AdV-tk was administered at doses of 1x 1012 vector particles (vp) (Cohort 1); 1x1013 vp (Cohort 2); and 1x1013 vp plus celecoxib (Cohort 3). Three pts were treated per cohort with 10 pts in the expansion phase. Valacyclovir (2 gm PO TID x 14 days) started the day after AdV-tk followed by chemotherapy. Secondary end-points included response rate, progression free survival, overall survival and immune response. Results: From 2013 to 2015, 19 pts were enrolled and completed therapy: median age 68 years (range 42-89), 14 malignant mesothelioma (MM) (9 epithelioid, 3 sarcomatoid, 2 biphasic), 4 non-small cell lung cancer (NSCLC) and 1 breast cancer. All 3 pts in cohort 2 experienced transient cytokine release syndrome (CRS), with fever, nausea and chills (grade 2) plus hypotension in 1 pt. Addition of prophylactic celecoxib in cohort 3 (n = 13) reduced the incidence and severity of CRS (23% grade 1, 23% grade 2). Response according to RECIST was evaluable for 16 pts, one pt with MM had a PR, 12 SD, and 3 PD. Eight pts are alive and in active follow up (5-17 months), 3 pts with NSCLC are on active treatment with PFS 6.8-10.6 months and OS 9.4-11.8 months. Immune studies on pt samples are ongoing, and will be presented at the meeting. Conclusions: GMCI can be safely administered at high-doses IP followed by systemic chemotherapy. CRS symptoms due to immune stimulation after IP AdV-tk can be diminished with celecoxib prophylaxis. Phase II studies are warranted to further determine efficacy. Clinical trial information: NCT01997190.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3081
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
3081 Background: GMCI is a tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followed by administration of an anti-herpetic prodrug. Immunogenic tumor cell death and superantigen-mediated T cell stimulation leads to CD8 T cell dependent protection against tumor challenge in preclinical models. Methods: The primary end-point of this dose escalation trialwas safety of GMCI followed by standard chemotherapy. Eligibility included patients (pts) with MPE with a clinical indication for placement of pleural catheter, age > 18 yrs, ECOG PS 0-1, FEV1 > 40% predicted and adequate end organ function. Intra-pleural (IP) AdV-tk was administered at doses of 1x 1012 vector particles (vp) (Cohort 1); 1x1013 vp (Cohort 2); and 1x1013 vp plus celecoxib (Cohort 3). Three pts were treated per cohort with 10 pts in the expansion phase. Valacyclovir (2 gm PO TID x 14 days) started the day after AdV-tk followed by chemotherapy. Secondary end-points included response rate, progression free survival, overall survival and immune response. Results: From 2013 to 2015, 19 pts were enrolled and completed therapy: median age 68 years (range 42-89), 14 malignant mesothelioma (MM) (9 epithelioid, 3 sarcomatoid, 2 biphasic), 4 non-small cell lung cancer (NSCLC) and 1 breast cancer. All 3 pts in cohort 2 experienced transient cytokine release syndrome (CRS), with fever, nausea and chills (grade 2) plus hypotension in 1 pt. Addition of prophylactic celecoxib in cohort 3 (n = 13) reduced the incidence and severity of CRS (23% grade 1, 23% grade 2). Response according to RECIST was evaluable for 16 pts, one pt with MM had a PR, 12 SD, and 3 PD. Eight pts are alive and in active follow up (5-17 months), 3 pts with NSCLC are on active treatment with PFS 6.8-10.6 months and OS 9.4-11.8 months. Immune studies on pt samples are ongoing, and will be presented at the meeting. Conclusions: GMCI can be safely administered at high-doses IP followed by systemic chemotherapy. CRS symptoms due to immune stimulation after IP AdV-tk can be diminished with celecoxib prophylaxis. Phase II studies are warranted to further determine efficacy. Clinical trial information: NCT01997190.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2580
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
2580 Background: This is an open-label, multi-arm, dose-escalation study (NCT01862328) of pev (TAK-924/MLN4924) plus chemotherapy in pts with solid tumors. Safety and preliminary efficacy results have been reported (Lockhart et al, AACR-NCI-EORTC 2015); common adverse events in pts treated with pev + carbo/pac were fatigue (50%), nausea (38%), and G3 elevated AST/ALT (19%). We present previously unreported antitumor activity in pts treated with this combination. Methods: Twenty-six pts received pev IV 15, 20, or 25 mg/m2 on d 1, 3, and 5 with carbo AUC5 + pac 175 mg/m2 on d 1 (lead-in cohort, n = 6: pev 15 mg/m2 + carbo AUC6) every 21 d. The combination appeared tolerable; MTD pev 20 mg/m2 + carbo AUC5 + pac 175 mg/m2. Response was assessed per RECIST v1.1; sparse PK sampling was carried out during C1. ERCC1 expression was assessed by IHC. Results: Nine responses were observed in 32 pts (28%) including those resistant to prior platinum/taxane therapy. Two pts (1 endometrial carcinoma, 1 bladder cancer) achieved a complete response (CR), and remain on study ( > 12 cycles). Seven pts (3 head and neck, 1 cholangiocarcinoma, 1 NSCLC, 1 sarcoma, 1 breast cancer) achieved a partial response (PR). The 9 responders received 4–18 cycles and had a median of 4 (range 1–8) prior therapies, including 4 with prior taxane (best response: 1 CR, 1 PR, 1 stable disease [SD], 1 unknown) and 8 with prior platinum (best response: 1 PR, 6 SD, 1 unknown). The majority had response within 2 cycles. Prolonged SD was seen in 3 pts (1 sarcoma, 1 endometrial cancer, 1 ovarian cancer), all 3 discontinued chemotherapy due to toxicity but continued to benefit from single-agent pev (SD duration 4.9–14.7 mos). Pev PK was unaffected in the presence of carbo/pac. Archival tumor sections from 23/30 pts were evaluable for ERCC1 staining. Conclusions: Pev+ carbo/pac showed broad-based antitumor activity in heavily pre-treated pts with solid tumors. Consistent with preclinical synergy between agents, lengthy treatment durations and improved responses in pts resistant to prior platinum/taxane therapy suggest the potential reversal of resistance by the addition of pev. Clinical trial information: NCT01862328.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2580
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
2580 Background: This is an open-label, multi-arm, dose-escalation study (NCT01862328) of pev (TAK-924/MLN4924) plus chemotherapy in pts with solid tumors. Safety and preliminary efficacy results have been reported (Lockhart et al, AACR-NCI-EORTC 2015); common adverse events in pts treated with pev + carbo/pac were fatigue (50%), nausea (38%), and G3 elevated AST/ALT (19%). We present previously unreported antitumor activity in pts treated with this combination. Methods: Twenty-six pts received pev IV 15, 20, or 25 mg/m2 on d 1, 3, and 5 with carbo AUC5 + pac 175 mg/m2 on d 1 (lead-in cohort, n = 6: pev 15 mg/m2 + carbo AUC6) every 21 d. The combination appeared tolerable; MTD pev 20 mg/m2 + carbo AUC5 + pac 175 mg/m2. Response was assessed per RECIST v1.1; sparse PK sampling was carried out during C1. ERCC1 expression was assessed by IHC. Results: Nine responses were observed in 32 pts (28%) including those resistant to prior platinum/taxane therapy. Two pts (1 endometrial carcinoma, 1 bladder cancer) achieved a complete response (CR), and remain on study ( > 12 cycles). Seven pts (3 head and neck, 1 cholangiocarcinoma, 1 NSCLC, 1 sarcoma, 1 breast cancer) achieved a partial response (PR). The 9 responders received 4–18 cycles and had a median of 4 (range 1–8) prior therapies, including 4 with prior taxane (best response: 1 CR, 1 PR, 1 stable disease [SD], 1 unknown) and 8 with prior platinum (best response: 1 PR, 6 SD, 1 unknown). The majority had response within 2 cycles. Prolonged SD was seen in 3 pts (1 sarcoma, 1 endometrial cancer, 1 ovarian cancer), all 3 discontinued chemotherapy due to toxicity but continued to benefit from single-agent pev (SD duration 4.9–14.7 mos). Pev PK was unaffected in the presence of carbo/pac. Archival tumor sections from 23/30 pts were evaluable for ERCC1 staining. Conclusions: Pev+ carbo/pac showed broad-based antitumor activity in heavily pre-treated pts with solid tumors. Consistent with preclinical synergy between agents, lengthy treatment durations and improved responses in pts resistant to prior platinum/taxane therapy suggest the potential reversal of resistance by the addition of pev. Clinical trial information: NCT01862328.
- 9 May 2011
- Published by Springer Nature
- p. 555-568
Management of Thyroid and Parathyroid Cancers
- Open Access
- 1 November 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (21) , 6694-6701
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Purpose: This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors. Experimental Design: In part 1, patients received escalating doses of danusertib (24-hour infusion every 14 days) without filgrastim (granulocyte colony-stimulating factor, G-CSF). Febrile neutropenia was the dose-limiting toxicity without G-CSF. Further dose escalation was done in part 2 with G-CSF. Blood samples were collected for danusertib pharmacokinetics and pharmacodynamics. Skin biopsies were collected to assess histone H3 phosphorylation (pH3). Results: Fifty-six patients were treated, 40 in part 1 and 16 in part 2. Febrile neutropenia was the dose-limiting toxicity in part 1 without G-CSF. Most other adverse events were grade 1 to 2, occurring at doses ≥360 mg/m2 with similar incidence in parts 1 and 2. The maximum tolerated dose without G-CSF is 500 mg/m2. The recommended phase 2 dose in part 2 with G-CSF is 750 mg/m2. Danusertib showed dose-proportional pharmacokinetics in parts 1 and 2 with a median half-life of 18 to 26 hours. pH3 modulation in skin biopsies was observed at ≥500 mg/m2. One patient with refractory small cell lung cancer (1,000 mg/m2 with G-CSF) had an objective response lasting 23 weeks. One patient with refractory ovarian cancer had 27% tumor regression and 30% CA125 decline. Conclusions: Danusertib was well tolerated with target inhibition in skin at ≥500 mg/m2. Preliminary evidence of antitumor activity, including a partial response and several occurrences of prolonged stable disease, was seen across a variety of advanced refractory cancers. Phase II studies are ongoing. (Clin Cancer Res 2009;15(21):6694–701)
- 1 November 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (21) , 6694-6701
Open AccessA Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Purpose: This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors. Experimental Design: In part 1, patients received escalating doses of danusertib (24-hour infusion every 14 days) without filgrastim (granulocyte colony-stimulating factor, G-CSF). Febrile neutropenia was the dose-limiting toxicity without G-CSF. Further dose escalation was done in part 2 with G-CSF. Blood samples were collected for danusertib pharmacokinetics and pharmacodynamics. Skin biopsies were collected to assess histone H3 phosphorylation (pH3). Results: Fifty-six patients were treated, 40 in part 1 and 16 in part 2. Febrile neutropenia was the dose-limiting toxicity in part 1 without G-CSF. Most other adverse events were grade 1 to 2, occurring at doses ≥360 mg/m2 with similar incidence in parts 1 and 2. The maximum tolerated dose without G-CSF is 500 mg/m2. The recommended phase 2 dose in part 2 with G-CSF is 750 mg/m2. Danusertib showed dose-proportional pharmacokinetics in parts 1 and 2 with a median half-life of 18 to 26 hours. pH3 modulation in skin biopsies was observed at ≥500 mg/m2. One patient with refractory small cell lung cancer (1,000 mg/m2 with G-CSF) had an objective response lasting 23 weeks. One patient with refractory ovarian cancer had 27% tumor regression and 30% CA125 decline. Conclusions: Danusertib was well tolerated with target inhibition in skin at ≥500 mg/m2. Preliminary evidence of antitumor activity, including a partial response and several occurrences of prolonged stable disease, was seen across a variety of advanced refractory cancers. Phase II studies are ongoing. (Clin Cancer Res 2009;15(21):6694–701)
- 1 December 2008
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 22 (6) , 1279-1295
New Agents in the Treatment for Malignancies of the Salivary and Thyroid Glands
- 1 December 2008
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 22 (6) , 1279-1295
New Agents in the Treatment for Malignancies of the Salivary and Thyroid Glands
- Open Access
- 16 May 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (11) , 1621-1626
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16 mg kg−1), receiving ATN-161 administered as a 10-min infusion thrice weekly. Pharmacokinetic sampling of blood and urine over 7 h was performed on Day 1. Twenty-six patients received from 1 to 14 4-week cycles of treatment. The total number of cycles administered to all patients was 86, without dose-limiting toxicities. At dose levels above 0.5 mg kg−1, mean total clearance and volume of distribution showed dose-independent pharmacokinetics (PKs). At 8.0 and 16.0 mg kg−1, clearance of ATN-161 was reduced, suggesting saturable PKs. Dose escalation was halted at 16 mg kg−1 when drug exposure (area under the curve) exceeded that associated with efficacy in animal models. There were no objective responses. Six patients received more than four cycles of treatment (>112 days). Three patients received 10 or more cycles (280 days). ATN-161 was well tolerated at all dose levels. Approximately, 1/3 of the patients in the study manifested prolonged stable disease. These findings suggest that ATN-161 should be investigated further as an antiangiogenic and antimetastatic cancer agent alone or with chemotherapy.
- 16 May 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (11) , 1621-1626
Open AccessPhase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five –amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1–16 mg kg−1), receiving ATN-161 administered as a 10-min infusion thrice weekly. Pharmacokinetic sampling of blood and urine over 7 h was performed on Day 1. Twenty-six patients received from 1 to 14 4-week cycles of treatment. The total number of cycles administered to all patients was 86, without dose-limiting toxicities. At dose levels above 0.5 mg kg−1, mean total clearance and volume of distribution showed dose-independent pharmacokinetics (PKs). At 8.0 and 16.0 mg kg−1, clearance of ATN-161 was reduced, suggesting saturable PKs. Dose escalation was halted at 16 mg kg−1 when drug exposure (area under the curve) exceeded that associated with efficacy in animal models. There were no objective responses. Six patients received more than four cycles of treatment (>112 days). Three patients received 10 or more cycles (280 days). ATN-161 was well tolerated at all dose levels. Approximately, 1/3 of the patients in the study manifested prolonged stable disease. These findings suggest that ATN-161 should be investigated further as an antiangiogenic and antimetastatic cancer agent alone or with chemotherapy.
- 1 February 2003
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 2 (4) , 246-251
Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer
- 1 February 2003
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 2 (4) , 246-251
Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer